EGFR and colorectal carcinoma: Cetuximab, an inhibitor of epidermal growth factor receptor, is no longer recommended for preoperative conversion therapy in patients with stage IV RSCRC (previously, the effect of cetuximab as the first-line treatment for patients with stage IV CRC has been confirmed, and some patients obtained surgery opportunity) (24–26).